Cory Abate-Shen, PhD

Academic Appointments

  • Professor of Pharmacology and Robert Sonneborn Professor of Medicine
  • Professor of Urologic Sciences (in Urology)
  • Professor of Pathology and Cell Biology and of Systems Biology (in the Herbert Irving Comprehensive Cancer Center and the Institute for Cancer Genetics)
  • Chair, Department of Pharmacology
Cory Abate-Shen, PhD

Dr. Abate-Shen began her independent career as an Assistant Professor at Rutgers Medical School in 1991, where she rose quickly through the ranks, becoming Professor, Chief of the Division of Research in the Department of Medicine, and co-leader of the Prostate Program for The Cancer Institute of New Jersey. In 2007, Dr. Abate-Shen was recruited to the faculty of Columbia University Vagelos College of Physicians and Surgeons as the Michael and Stella Chernow Professor of Urological Oncology, at the Herbert Irving Comprehensive Cancer Center (HICCC), with appointments in the Departments of Urology, Pathology & Cell Biology, Medicine, Systems Biology, and the Institute of Cancer Genetics. In 2008, she was appointed Associate Director at the HICCC, and served as its Interim Director in 2012 as well as in 2017-2018. In 2019, she was appointed as Chair of the Department of Pharmacology, and the Robert Sonneborn Professor of Pharmacology at Columbia University Vagelos College of Physicians and Surgeons

Dr. Abate-Shen is an internationally-recognized leader in genitourinary malignancies. Her innovative studies of genetically-engineered mouse models for these cancers have led to the discovery of new biomarkers for early detection, as well as advances in cancer prevention and treatment. In recognition of her achievements, Dr. Abate-Shen has been the recipient of numerous awards, including a Sinsheimer Scholar Award, an NSF Young Investigator Award, and an American Cancer Society Research Professorship, the first to be awarded at Columbia University Medical Center. She has served on the Board of Scientific Counselors of the National Cancer Institute, as well as on its Blue Ribbon Panel Working Group for the Cancer Moonshot Initiative. Dr. Abate-Shen has served in various leadership roles in the American Association for Cancer Research including a member of its Board of Directors. Dr. Abate-Shen has also participated extensively in national grant review sections including as the chair of the NIH Molecular Oncology Study Section. Recently, she has been elected as a fellow of the American Association for the Advancement of Science.

Dr. Abate-Shen’s research focuses on the molecular mechanisms of cancer development. She has a longstanding commitment to the generation of mouse models of cancer and their effective use for translational research. Her major research interests are in the area of genitourological cancer. Most notably, her laboratory has developed novel models of prostate and bladder cancer, which have been utilized for investigating the molecular basis of the disease as well as preclinical models for evaluating new therapies.

Departments and Divisions

  • Department of Molecular Pharmacology and Therapeutics
  • Department of Urology
  • Department of Pathology & Cell Biology

Centers / Institutes / Programs

  • Herbert Irving Comprehensive Cancer Center

Lab Locations

  • Irving Cancer Research Center

    1130 St. Nicholas Avenue
    321 3
    New York, NY 10032

Research Interests

  • Genitourinary cancer development
  • Molecular mechanisms of cancer development

NIH Grants

  • MITOCHONDRIAL AND NUCLEAR FUNCTIONS OF NKX3.1 IN REGULATING OXIDATIVE STRESS IN PROSTATE CANCER (Federal Gov)

    Dec 1 2018 - Nov 30 2023

    MODELING BLADDER CANCER PATHOGENESIS AND TUMOR EVOLUTION (Federal Gov)

    Sep 11 2018 - Aug 31 2023

    PRECLINICAL ANALYSES OF ADVANCED PROSTATE CANCER IN GENETICALLY-ENGINEERED MICE (Federal Gov)

    Feb 14 2018 - Jan 31 2023

    MOLECULAR DETERMINANTS OF PROSTATE CANCER PROGRESSION (Private)

    Jan 1 2016 - Dec 31 2021

    CENTERS FOR CANCER SYSTEMS THERAPEUTICS (CAST) (Federal Gov)

    Aug 8 2016 - Jul 31 2021

    TARGETING ERCC2 TO OVERCOME CHEMOTHERAPY RESISTANCE IN METASTATIC BLADDER CANCER (Private)

    Jul 1 2019 - Jun 30 2021

    THET.J. MARTELL FOUNDATION FOR LEUKEMIA, CANCER AND AIDS RESEARCH (Private)

    Jan 1 2015 - Dec 31 2020

    INVESTIGATING THE CELL OF ORIGIN OF BLADDER CANCER (Federal Gov)

    Apr 1 2015 - Sep 30 2020

    MOLECULAR MECHANISMS OF PROSTATE CANCER METASTASIS (Federal Gov)

    Jan 1 2015 - Jun 30 2020

    INVESTIGATING THE CELL OF ORIGIN OF BLADDER CANCER (Federal Gov)

    Apr 1 2015 - Mar 31 2020

    MOLECULAR MECHANISMS OF PROSTATE CANCER METASTASIS (Federal Gov)

    Jan 1 2015 - Dec 31 2019

    MOLECULAR MECHANISMS OF PROSTATE CANCER METASTASIS (Federal Gov)

    Jan 1 2015 - Dec 31 2019

    CANCER CENTER SUPPORT GRANT (Federal Gov)

    Jul 1 2014 - Jun 30 2019

    CANCER CENTER SUPPORT GRANT (Federal Gov)

    Jul 1 2014 - Jun 30 2019

    ANALYSIS OF DRUG RESPONSE IN ORGANOIDS AND MOUSE MODELS (Federal Gov)

    Jul 1 2016 - Jun 30 2019

    CANCER CENTER SUPPORT GRANT (Federal Gov)

    Jul 1 2014 - Jun 30 2019

    CHARACTERIZATION OF EPIGENETIC REGULATORY DRIVERS OF PROSTATE CANCER METASTASIS (Federal Gov)

    Sep 15 2016 - Sep 14 2018

    PRECLINICAL ANALYSES OF ADVANCED PROSTATE CANCER IN GENETICALLY-ENGINEERED MICE (Federal Gov)

    Aug 6 2013 - May 31 2018

    PRECLINICAL ANALYSES OF ADVANCED PROSTATE CANCER IN GENETICALLY-ENGINEERED MICE (Federal Gov)

    Aug 6 2013 - May 31 2018

    PRECLINICAL ANALYSES OF ADVANCED PROSTATE CANCER IN GENETICALLY-ENGINEERED MICE (Federal Gov)

    Aug 6 2013 - May 31 2018

    CHARACTERIZATION OF EPIGENETIC REGULATORY DRIVERS OF PROSTATE CANCER METASTASIS (Federal Gov)

    Nov 1 2015 - Oct 31 2017

    FUNCTIONAL IDENTIFICATION OF MASTER REGULATORS OF PROSTATE CANCER METASTASIS THROUGH CRISPR/CAS9 SCREENING (Federal Gov)

    Jul 1 2015 - Aug 16 2017

    EPIGENETIC REGULATION OF BLADDER CANCER PROGRESSION (Private)

    Jul 15 2015 - Jul 14 2017

    RESEARCH FOR A 5-GENE PANEL (PRO-SCOPE) FOR IMPROVED EARLY DIAGNOSIS OF PROSTATE CANCER (Private)

    Mar 6 2015 - Mar 5 2017

    MOLECULAR MECHANISMS OF PROSTATE CANCER INITIATION (Federal Gov)

    Sep 16 2011 - Feb 28 2017

    MOLECULAR DETERMINANTS OF PROSTATE CANCER PROGRESSION (Private)

    Jan 1 2012 - Dec 16 2016

    NATIONAL CENTER: MULTISCALE ANALYSIS OF GENOMIC AND CELLULAR NETWORKS (MAGNET) (Federal Gov)

    Sep 26 2005 - Jul 31 2016

    CELL OF ORIGIN OF BLADDER CANCER (Private)

    Jul 1 2014 - Jun 30 2016

    INVESTIGATING THE CELL OF ORIGIN OF BLADDER CANCER (Federal Gov)

    Apr 1 2015 - Mar 31 2016

    INVESTIGATING THE CELL OF ORIGIN OF BLADDER CANCER (Federal Gov)

    Apr 1 2015 - Mar 31 2016

    ANALYSES OF THE ROLE OF P53 IN ABIRATERONE RESPONSE (Private)

    Jul 1 2014 - Nov 14 2014

    LEADERSHIP COMPONENT IN CHEMOPREVENTION: MOUSE MODELS OF HUMAN CANCER CONSORTIUM (Federal Gov)

    Sep 1 2009 - Aug 31 2014

    ELUCIDATION OF CANCER PATHWAYS AND DRUGGABLE TARGETS USING MOUSE MODELS (Federal Gov)

    Sep 30 1999 - Jul 31 2014

    PRECLINICAL INVESTIGATIONS OF FINASTERIDE IN MOUSE MODELS OF PROSTATE CANCER (Federal Gov)

    Jul 1 2012 - May 31 2014

    PRE-CLINICAL AND CLINICAL APPROACHES FOR DEVELOPING NEW TREATMENTS FOR CASTRATION-RESISTANT PROSTATE CANCER (Private)

    Sep 1 2010 - Aug 31 2013

    ASSEMBLY OF A PROSTATE CANCER GENOME-WIDE MOLECULAR INTERACT OME FOR THE IDENTIFICATION OF THE KEY REGULATORY GENES OF MA (Private)

    Aug 1 2010 - Jul 31 2013

    THEUSE OF INTRAVESICAL CABAZITAXEL, GEMCITABINE, AND CISPLA TIN (CGC) IN THE TREATMENT OF HIGH RISK NON-MUSCLE INVASIVE (Private)

    Jul 1 2012 - Jun 30 2013

    MOLECULAR MECHANISMS OF INVASIVE BLADDER CANCER: ANALYSIS OF ARF FUNCTION IN P53/PTEN (Private)

    Jul 1 2011 - Jun 30 2012

    NOVEL THERAPEUTIC TARGETS IN INVASIVE BLADDER CANCER (Private)

    Jul 1 2011 - Jun 30 2012

    MODELING ANDROGEN-INDEPENDENT PROSTATE CANCER IN MUTANT MICE (Federal Gov)

    Apr 1 2007 - Jan 31 2012

    NEXT-GENERATION MOUSE MODELS OF PROSTATE CANCER PROGRESSION AND METASTASES (Private)

    Jul 1 2008 - Jun 30 2011

    ANALYSES OF EARLY STAGE PROSTATE CARCINOGENESIS: TARGETING T HE NFKB PATHWAY FOR EARLY INTERVENTION (Private)

    Jul 1 2009 - Jun 30 2011

    PRECLINICAL TESTING OF MTOR AND AKT INHIBITORS ON A MOUSE MO DEL OF PROSTATE CANCER (Private)

    Jun 24 2009 - Jun 23 2011

    PRECLINICAL STUDIES OF SIGNALING PATHWAY IN A MUTANT MOUSE M ODEL OF HORMONE-REFRACTORY PROSTATE CANC (Federal Gov)

    Jan 28 2008 - Apr 30 2011

    ROLE FOR MSX1 IN VERTEBRATE EMBRYOGENSIS (Federal Gov)

    Aug 1 1992 - Nov 30 2009

    CHEMOPREVENTION OF PROSTATE CANCER IN MUTANT MICE: TARGETING THE ANDROGEN RECEPTOR SIGNALING PATHWAY (Federal Gov)

    Dec 2 2007 - Nov 14 2009

Publications

Selected Reviews and Commentaries

Complete List of Published Work

https://www.ncbi.nlm.nih.gov/myncbi/cory.abate-shen.1/bibliography/public/